These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 24170083)

  • 1. [Special considerations for the regulation of biological medicinal products in individualised medicine. More than stratified medicine].
    Müller-Berghaus J; Volkers P; Scherer J; Cichutek K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1538-44. PubMed ID: 24170083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Importance of bioinformatics in personalised medicine].
    Lengauer T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1489-94. PubMed ID: 24170077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The relevance of biomarkers for personalised medicine].
    Großhennig A; Benda N; Koch A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1480-8. PubMed ID: 24084852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Personalised medicine. Aims and challenges].
    Bieber T; Broich K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1468-72. PubMed ID: 24170075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Strategic considerations on the design and choice of animal models for non-clinical investigations of cell-based medicinal products].
    Lehmann J; Schulz RM; Sanzenbacher R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1215-24. PubMed ID: 26431722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science?
    Marquet P; Longeray PH; Barlesi F; ; Ameye V; Augé P; Cazeneuve B; Chatelut E; Diaz I; Diviné M; Froguel P; Goni S; Gueyffier F; Hoog-Labouret N; Mourah S; Morin-Surroca M; Perche O; Perin-Dureau F; Pigeon M; Tisseau A; Verstuyft C
    Therapie; 2015; 70(1):1-19. PubMed ID: 25679189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
    Lucas-Samuel S; Ferry N; Trouvin JH
    Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products.
    Lowdell MW; Thomas A
    Br J Haematol; 2017 Jan; 176(1):9-15. PubMed ID: 27748517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining drug response for stratified medicine.
    Lonergan M; Senn SJ; McNamee C; Daly AK; Sutton R; Hattersley A; Pearson E; Pirmohamed M
    Drug Discov Today; 2017 Jan; 22(1):173-179. PubMed ID: 27818254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Personalised medicine for the diagnosis and treatment of allergic diseases].
    Vieths S; Bieber T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1531-7. PubMed ID: 24170082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].
    Stingl JC; Just KS; Kaumanns K; Schurig-Urbaniak M; Scholl C; von Mallek D; Brockmöller J
    Internist (Berl); 2016 Mar; 57(3):289-97. PubMed ID: 26830424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Personalised medicine. Paradigm shift within drug research and therapy].
    Stock G; Sydow S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1495-501. PubMed ID: 24170078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Exemplary cases of individualization of biological therapy].
    Sipponen T; Isomäki P; Leinonen S; Mälkönen T; Jokiranta S
    Duodecim; 2016; 132(4):387-90. PubMed ID: 27017791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized medicine and economic evaluation in oncology: all theory and no practice?
    Garattini L; Curto A; Freemantle N
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):733-8. PubMed ID: 26289733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical assessment of biosimilar products.
    Chow SC; Liu JP
    J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical pharmacologic principles of the development and application of follow-on biological medicinal products].
    Kerpel-Fronius S
    Orv Hetil; 2007 May; 148(20):915-21. PubMed ID: 17509971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Classification of cell-based medicinal products and legal implications: An overview and an update].
    Scherer J; Flory E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1201-6. PubMed ID: 26369760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.